MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

doi:10.1182/blood-2014-04-572545

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

Blood - 14 Aug 2014

Rondelli Damiano, Goldberg Judith D, Isola Luis, Price Leah S, Shore Tsiporah B, Boyer Michael, Bacigalupo Andrea, Rambaldi Alessandro, Scarano Marco, Klisovic Rebecca B, Gupta Vikas, Andreasson Bjorn, Mascarenhas John, Wetzler Meir, Vannucchi Alessandro M, Prchal Josef T, Najfeld Vesna, Orazi Attilio, Weinberg Rona S, Miller Crystal, Barosi Giovanni, Silverman Lewis R, Prosperini Giuseppe, Marchioli Roberto, Hoffman Ronald

Abstract excerpt

From 2007 to 2011, 66 patients with primary myelofibrosis or myelofibrosis (MF) preceded by essential thrombocythemia or polycythemia vera were enrolled into a prospective phase 2 clinical trial of reduced-intensity allogeneic hematopoietic stem cell transplantation (AHSCT), Myeloproliferative Disorder Research Consortium 101 trial. The study included patients with sibling donors (n = 32) receiving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Donors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft vs Host Disease

Share to Histocompatibility

Share to Melphalan

Share to Primary Myelofibrosis

Share to Transplantation Conditioning

Share to Unrelated Donors

Share to Vidarabine

Source

Open in PubMed Open full text

Identifiers

PMID: 24963042
DOI: 10.1182/blood-2014-04-572545
PMCID: PMC4133490

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.PMID 24963042Read ↗

Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.Semantic proximity Read ↗

Allogeneic stem cell transplantation for myelofibrosis in 2012.Semantic proximity Read ↗

Haplo‐identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMTSemantic proximity Read ↗

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?Semantic proximity Read ↗

Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.Semantic proximity Read ↗

Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.Semantic proximity Read ↗

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficienciesSemantic proximity Read ↗

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decadesSemantic proximity Read ↗

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review.Semantic proximity Read ↗

Alternative donor hematopoietic cell transplantation for Fanconi anemiaSemantic proximity Read ↗

Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.Semantic proximity Read ↗

Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American CollaborationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.